Compared with the therapeutic response in overall enrolled patients, ORR was markedly higher in BRCA1/2 mutated patients (ORR of BRCA1/2 mutated vs. overall patients in breast cancer cohort, 67% vs. 29%; ORR of BRCA1/2 mutated vs. overall patients in ovarian cancer cohort, 45% vs. 25%) [127, 128]. Here, BRCA1 is linked to breast carcinoma.